drugset / Trial / NCT00003153

Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation

NCT00003153

Treatment

Summary

RATIONALE: White blood cells from donors may be able to kill cancer cells in patients with multiple myeloma that has recurred following bone marrow transplantation. PURPOSE: This phase II trial is studying how well giving donor white blood cells works in treating patients with recurrent multiple myeloma who have undergone bone marrow transplantation.

Timeline

Start
1998-07-22
Primary completion
2007-02
Completion
2009-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject therapeutic allogeneic lymphocytes Cell therapy Intravenous

Indications